Eucrates Biomedical Acquisition Corp.
CIK 0001822929
Revenue (TTM)
—
FY Apr 2023
Net Income (TTM)
$3.23M
−36.7% YoY
FY Apr 2023
EPS Diluted (TTM)
—
FY Apr 2023
Gross Margin
—
FY Apr 2023
Operating Margin
—
FY Apr 2023
Net Margin
—
FY Apr 2023
Free Cash Flow (TTM)
—
FY Apr 2023
Cash
$18.87K
FY Apr 2023
Total Debt
—
FY Apr 2023
Shares Outstanding
4.21M sh
FY Apr 2023
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.